Patents by Inventor Hiroyasu Nishioka

Hiroyasu Nishioka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050148634
    Abstract: Provided are 1-N-aminobenzimidazole derivatives represented by the following formula (I): wherein R1 and R2 each represents a substituted or unsubstituted alkyl group or the like, R3, R5 and R6 each represents an alkyl group, alkoxy group, hydrogen atom or the like, R4 represents a substituted or unsubstituted alkyl group or the like, A represents a benzene ring or the like, B represents a hydrogen atom or the like, an n stands for an integer of from 0 to 2, or salts thereof; and medicines containing them. The compounds (I) according to the present invention do not bring about much individual differences in therapeutic effects despite the existence of individual differences in the CYP2C19 activity. At the same dose, they can hence bring about appropriate therapeutic effects for all patients. In addition, they are low in the risk of induction of an interaction or a cancer caused by induction of the CYP1A family.
    Type: Application
    Filed: March 28, 2003
    Publication date: July 7, 2005
    Applicant: ZERIA PHARMACEUTICAL CO., LTD
    Inventors: Masaaki Nagasawa, Hiroyasu Nishioka, Kazuyasu Asami, Naoyoshi Miura, Hideki Nakamura, Hitoshi Morita
  • Patent number: 6884810
    Abstract: A benzimidazole derivative of formula (1): (wherein R represents a hydrogen atom or a methoxy group, and n is 0 or 1) or a salt thereof; and a medicament containing the same. The compounds of the present invention, due to minimized difference in therapeutic effect between subjects, which difference would otherwise be derived from different CYP2C19 activity from subject to subject, ensure that all patients can enjoy proper therapeutic effects at the same dose of the drug. Also, the compounds of the invention have low risk of drug interaction caused by induction of CYP1A family member enzymes, as well as low risk of development of cancer, and thus is useful as a remedy for peptic ulcer, reliably providing therapeutic effects with safety.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: April 26, 2005
    Assignee: Zeria Pharmaceutical Co., Ltd.
    Inventors: Masaaki Nagasawa, Hiroyasu Nishioka, Kazuyasu Asami, Naoyoshi Miura, Yutaka Shinozaki, Hitoshi Morita
  • Patent number: 6673368
    Abstract: Remedies effective for the improvement of colonic motor dysfunction such as irritable bowel syndrome, constipation or intestinal atony without causing side effects on the central nerve system. These colonic motor dysfunction remedies comprise, as active ingredients, aminothiazole derivatives represented by the following formula (I) or a salt or hydrate thereof: wherein R1, R2 and R3 may be the same or different and each independently represent a hydrogen atom or a hydroxyl, lower alkyl, lower alkoxy, amino, nitro or cyano group, R4 and R5 may be the same or different and each independently represent a hydrogen atom or a lower alkyl group, and n stands for an integer of from 2 to 4.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: January 6, 2004
    Assignee: Zeria Phamaceutical Co., Ltd.
    Inventors: Shigeru Ueki, Yuko Hori, Yugo Matsunaga, Masaaki Nagasawa, Hiroyasu Nishioka, Masakazu Murata
  • Publication number: 20030236411
    Abstract: A benzimidazole derivative of formula (1): 1
    Type: Application
    Filed: March 17, 2003
    Publication date: December 25, 2003
    Inventors: Masaaki Nagasawa, Hiroyasu Nishioka, Kazuyasu Asami, Naoyoshi Miura, Yutaka Shinozaki, Hitoshi Morita
  • Patent number: 6562373
    Abstract: Remedies effective for the improvement of colonic motor dysfunction such as irritable bowel syndrome, constipation or intestinal atony without causing side effects on the central nerve system. These colonic motor dysfunction remedies comprise, as active ingredients, aminothiazole derivatives represented by the following formula (I) or a salt or hydrate thereof: wherein R1, R2 and R3 may be the same or different and each independently represent a hydrogen atom or a hydroxyl, lower alkyl, lower alkoxy, amino, nitro or cyano group, R4 and R5 may be the same or different and each independently represent a hydrogen atom or a lower alkyl group, and n stands for an integer of from 2 to 4.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: May 13, 2003
    Assignee: Zeria Pharmaceutical Co., Ltd.
    Inventors: Shigeru Ueki, Yuko Hori, Yugo Matsunaga, Masaaki Nagasawa, Hiroyasu Nishioka, Masakazu Murata
  • Publication number: 20020051805
    Abstract: Remedies effective for the improvement of colonic motor dysfunction such as irritable bowel syndrome, constipation or intestinal atony without causing side effects on the central nerve system.
    Type: Application
    Filed: May 14, 2001
    Publication date: May 2, 2002
    Applicant: ZERIA PHARMACEUTICAL CO., LTD.
    Inventors: Shigeru Ueki, Yuko Hori, Yugo Matsunaga, Masaaki Nagasawa, Hiroyasu Nishioka, Masakazu Murata
  • Patent number: 6197970
    Abstract: The present invention is directed to a process for producing 2-hydroxybenzamide derivatives (2) or (5) according to either one of the following reaction schemes.
    Type: Grant
    Filed: December 23, 1999
    Date of Patent: March 6, 2001
    Assignee: Zeria Pharmaceutical Co., Ltd.
    Inventors: Masaaki Nagasawa, Hiroyasu Nishioka, Takanori Suzuki, Eiichi Nagano, Katsuyuki Ishii, Ryu Nakao
  • Patent number: 5981557
    Abstract: The present invention relates to an aminothiazole derivative represented by the following formula (I): ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 each independently represents a hydrogen atom, a hydroxy group, a lower alkyl group, a lower alkoxy group or the like; R.sup.4 represents a hydrogen atom or a lower alkyl group; R.sup.5 represents a hydrogen atom, a halogen atom or a lower alkyl group; m stands for an integer of 0 to 4, A represents a substituted amino group, a substituted imino group, a heterocyclic group or the like; and B stands for an imino group or an oxygen atom, a medicament containing it and an intermediate for the preparation of said compound. The compound has strong restoration effects on dysmotility in the gastrointestinal tract and at the same time has high safety so that it is useful as an excellent gastroprokinetic.
    Type: Grant
    Filed: November 18, 1997
    Date of Patent: November 9, 1999
    Assignee: Zeria Pharmaceutical Co., Ltd.
    Inventors: Masaaki Nagasawa, Masakazu Murata, Hiroyasu Nishioka, Tadashi Kurimoto, Shigeru Ueki, Osamu Kitagawa
  • Patent number: 5407950
    Abstract: Arylalkanoylamine derivatives having excellent prolyl endopeptidase inhibitory action and resistances to hypoxia and amnesia which are represented by the following general formula (I): ##STR1## wherein A represents an indanyl, indenyl, 1,2,3,4-tetrahydronaphthalenyl or benzofuranyl group; m represents an integer of 0 to 5; Z represents a hydroxymethyl, formyl, nitrile, hydroxyiminomethyl, semicarbazonomethyl or dialkoxymethyl group; X and Y may be the same or different, and individually represent a methylene group or sulfur atom, wherein compounds defined by the following substituents are excluded: A represents an indanyl, indenyl, or 1,2,3,4-tetrahydronaphthalenyl group; X and Y each represent a methylene group; and Z represents a hydroxymethyl or formyl group. Also disclosed is a pharmaceutical composition and method for improving mneme, cerebral circulation and cerebral metabolism comprising the arylalkanoylamine derivatives as the effective ingredient.
    Type: Grant
    Filed: December 7, 1992
    Date of Patent: April 18, 1995
    Assignee: Zeria Pharmaceutical Co., Ltd.
    Inventors: Akihiro Okubo, Hiroyasu Nishioka, Heihachiro Arai, Yoshiaki Tanaka, Hisayoshi Kato, Naoki Nakata